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Human fibroblasts secrete  insulin-like  growth fac- 
tor-binding proteins (IGFBPs) that can modify insulin- 
like growth  factor (IGF) I action. We have determined 
the molecular identities of three forms of IGFBPs that 
are secreted by  human fibroblasts in vitro. Ligand blot 
analysis of fibroblast conditioned media revealed that 
the M, 43,000  and 39,000 forms were  the most abun- 
dant, but that M, 31,000 and  24,000 forms were also 
present. An antiserum that was specific for IGFBP-5 
reacted  with  the M, 31,000 form, and  an IGFBP-4- 
specific antiserum recognized  only the M, 24,000 form. 
The M, 39,000  and  43,000 forms were detected by 
IGFBP-3 antiserum. Further proof that fibroblasts 
synthesized these forms of IGFBPs was obtained by 
Northern blotting. A cDNA probe for IGFBP-3 hybrid- 
ized with a 2.4-kilobase (kb) transcript, whereas a 
cDNA probe for IGFBP-5 recognized a single 6.0-kb 
transcript, and an IGFBP-4 cDNA probe recognized 
2.2- and 2.0-kb transcripts. IGF-I and -11 caused a 
minimal (<43%) increase in IGFBP-5 mRNA abun- 
dance and had no effect on IGFBP-4 mRNA abundance. 
IGF-I and -11 (100 ng/ml) stimulated 6-&fold increases 
in IGFBP-5 levels, whereas IGFBP-4 was inhibited. 
Insulin failed to elicit any change in IGFBP-5, sug- 
gesting  that binding of the IGFs to IGFBPs was re- 
quired to detect the increase. Immunoblotting for 
IGFBP-5 revealed an M, 23,000 (non-IGF-I-binding) 
fragment. To determine if the IGFs were influencing 
proteolytic degradation of IGFBP-5, pure IGFBP-5 
was added to fibroblast. cultures  and incubated for  4  h 
at  37 OC. The amount of fragment formation was  atten- 
uated by the presence of IGF-I and -11, but not insulin, 
suggesting that  this  is a mechanism  by which the IGFs 
act to modulate IGFBP-5 concentration. In contrast to 
the IGFs, forskolin, which increased IGFBP-4 and -5 
mRNA abundance and secretion, had  no effect on frag- 
ment formation. The results show that human fibro- 
blasts synthesize and  secrete IGFBP-3, -4,  and -5 and 
that changes in  intracellular CAMP regulate synthesis, 
whereas  the IGFs regulate IGFBP-4 and -5 levels by 
post-transcriptional mechanisms. 
growth factors (IGFs)’ I and I1 and their specific binding 
proteins (IGFBPs) (1). Human dermal fibroblasts have been 
used as a model system to determine the factors that regulate 
the secretion of IGF-I and -11 (2, 3) and  to study their effects 
on fibroblast replication (4). Purified IGF-I-like peptides that 
are secreted by fibroblasts have been shown to bind to IGF-I 
receptors on the fibroblast surface (5); however, the fate of 
the secreted IGF-like peptides prior to receptor binding has 
not been determined. In addition  to IGF-like peptides, human 
fibroblasts secrete several forms of IGFBPs (6). The exact 
molecular identities of each of the forms of IGFBPs that are 
secreted by human fibroblasts have not yet been determined; 
however, two of these forms ( M I  43,000 and 39,000) can be 
specifically immunoprecipitated with an  IGFBP-3 antiserum 
(7). These two immunoreactive forms of IGFBP-3 are believed 
to be glycosylation variants of the same protein.  Fibroblasts 
also secrete an M,, 31,000 form of IGFBP  that could not be 
immunoprecipitated with an antisera to  IGFBP-1 (7). How- 
ever, a different antiserum  prepared  against  pure  IGFBP-1 
did react with this M, 31,000 form in  concentrated conditioned 
medium (6). This M,  31,000 form was shown to be increased 
6-&fold following IGF-I treatment (6). An additional M, 
24,000 form is present in fibroblast conditioned media, and 
its identity has not been determined. Because IGFBPs can 
modify the growth response of human fibroblasts to IGF-I (8, 
9),  it is important  to determine the molecular identities of the 
M,  31,000 and 24,000 forms and  to examine the variables that 
regulate secretion of these IGFBPs. This information will  be 
necessary to determine if these  proteins also have a role  in 
regulating the fibroblast growth response to  IGF-I. Therefore, 
the purpose of this study was to determine the molecular 
identities of the M,  31,000 and 24,000 IGFBP forms and  to 
analyze the mechanisms that regulate their secretion. 
EXPERIMENTAL  PROCEDURES 
Materials-EMEM was purchased from Hazelton (Denver, PA). 
Calf serum was purchased from Colorado Laboratories, Inc. (Logan, 
VT). Cycloheximide, Cohn fraction V, BSA, polyethylene glycol 8000, 
dexamethasone, hydrocortisone, progesterone, 17P-estradio1, ammo- 
nium persulfate, sodium phosphate, isopropyl-1-thio-P-D-galactopy- 
ranoside, and 5-bromo-4-chloro-3-indolyl P-D-galactoside were ob- 
tained from Sigma. Human y-globulins were purchased as  an 18% 
solution (Cutter Biological, Berkeley, CA). Recombinant human  in- 
sulin was purchased from Lilly. lZ5I-IGF-I (150-250 pCi/pg) was 
prepared by a previously described method  (10).  Recombinant  human 
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IGF-I and -11 were obtained from Bachem, Inc. (Torrance, CA). 
Human platelet-derived growth factor was purchased from PDGF, 
Inc.  (Boston, MA); and recombinant human basic fibroblast growth 
factor was provided by Dr. A. Sommer (Synergen, Boulder, CO). 
TGF-/3 from porcine platelets was obtained from R & D  Systems, Inc. 
(Minneapolis, MN); phenyl-Sepharose  CL-4B and oligo(dT)-cellulose 
were obtained from Pharmacia LKB Biotechnology Inc. Tris, sodium 
dodecyl sulfate (SDS), Temed, RNA and DNA ladders, and polyacryl- 
amide were purchased from Bethesda Research Laboratories.  Urea, 
acetonitrile, EDTA, isoamyl alcohol, and Tween 20 were obtained 
from Fisher.  Trifluoroacetic  acid was purchased from Pierce Chemical 
Co. Glycine, bromphenol blue, and glycerol were from Serva  (Heidel- 
berg, Federal Republic of Germany). Agarose (Sea Kem, Seaplaque, 
and NuSieve) was obtained from FMC  Bioproducts  (Rockland, ME). 
A Mighty Small 2 gel apparatus (Hoefer Scientific Instruments,  San 
Francisco, CA) was used for protein electrophoresis. Transfer of 
proteins to nitrocellulose filters (Schleicher and Schuell) was per- 
formed using a semidry electroblotter (Janssen Life Sciences, Pisca- 
taway, NJ). Autoradiograph X-Omat RP film was purchased from 
Eastman Kodak Co. The reagents used in cDNA sequencing were 
bought from United States Biochemical Corp., and  the reagents used 
in PCR were obtained from Perkin-Elmer Cetus Instruments.  PCR 
was performed in a  Perkin-Elmer  Cetus thermocycler. 35S-dATP, [CY- 
"'PIdCTP, and Rainbow high molecular weight standards were pur- 
chased from Amersham Corp. The  pBS vector was obtained from 
Stratagene  (San Diego, CA). Phenol,  ethidium bromide, and trypsin 
were purchased from Boehringer Mannheim. DNA restriction  endo- 
nuclease and modifying enzymes were purchased from Promega Bio- 
tec.  Tissue  culture  plates were obtained from Falcon Labware (Bec- 
ton, Dickinson & Co., Oxnard, CA), and calf serum was obtained 
from Colorado Serum Co. (Denver, CO). 
Cell Cultures-Human fetal dermal fibroblasts (GM10, Human 
Mutant Genetic Cell Repository,  Camden NJ) were cultured in 10- 
cm dishes using EMEM supplemented  with  serine (21 pg/ml),  pyru- 
vate (110 pg/ml), asparagine (30 pglml), penicillin (100 units/ml), 
streptomycin (100 pg/ml), and 10% calf serum. Cells were passaged 
weekly using phosphate-buffered  saline  plus 0.1% trypsin and 0.02 M 
EDTA and were replated at  a  density of 1 X lo4 cells/cm2 in either 
24- or 6-well tissue  culture  plates. The medium was replaced on the 
3rd day after plating, and cells were used on day 6 or 7. Cells were 
used between passages 8 and 14. For the experiments, cells were 
washed twice with serum-free EMEM  and  then incubated in 0.5 ml 
of EMEM supplemented with 0.01% BSA with or without other 
additives for 24 h. Conditioned media were collected and  stored at  
-20 "C for further analysis. SV40-transformed human fetal lung 
fibroblast (AG2804) cultures were obtained from the Aging Cell 
Repository (Camden, NJ)  and were maintained as described previ- 
ously (11). 
Preparation of Conditioned Medium for IGFBP Purification-A 
human glioblastoma tumor cell line  (T98G; American Type  Culture 
Collection, Rockville, MD) was grown to confluence in EMEM sup- 
plemented with 10% calf serum in Nunc cell factories (Roskilde, 
Denmark). Confluent cultures were then maintained in serum-free 
minimum  essential medium without  phenol red for 48 h,  and condi- 
tioned medium was harvested and stored at  -20 "C. Approximately 
19  liters of conditioned medium were collected in this  manner. 
Preparation of Cellular Extracts-Cellular proteins were extracted 
using the procedure of Knudsen et al. (12). Briefly, cells were plated 
in 6-well plates  and grown to confluence. Conditioned media samples 
were collected in siliconized tubes, and  the cells were washed twice 
with  phosphate-buffered  saline and  then solubilized with phosphate- 
buffered saline containing 0.5% Triton X-100 for 20 min at  room 
temperature. Cellular extracts were transferred  to siliconized tubes, 
lyophilized to dryness, and then redissolved in H20  and stored at  
-20 "C. 
IGFBP Purification-Nineteen liters of T98G cell-conditioned me- 
dium were centrifuged at  16,000 X g for 30 min to remove cellular 
debris; the  pH was adjusted to 7.2; and  the  salt concentration was 
increased to 0.5 M NaCl. Aliquots (1.5 liters) were loaded onto a 
phenyl-Sepharose column (4.4 X 5.7 cm) previously equilibrated  with 
0.05 M NaH2P04, 0.15 M NaC1, 0.002 M EDTA, pH 6.6. After sample 
loading, the column was washed with the same buffer until the 
absorbance (280 nm) returned to base  line. Proteins were eluted  using 
a linear  gradient of 0-100% elution buffer (0.04 M NaH2P04, 1.7 mM 
EDTA, 15% acetonitrile, pH 6.6) over 2 h. Twelve-milliliter fractions 
were collected, and 20 p1 of a 1:50 dilution of each fraction were 
assayed for IGF binding activity. Pools of active fractions were 
subjected to ligand blotting to determine the molecular weight esti- 
mates of each form of IGFBP present. The binding  protein  activity 
eluted as a single broad peak between 10 and 15% acetonitrile. 
Recovery ranged between 60 and 90%. The fractions  containing  IGF 
binding  activity were pooled; the acetonitrile was removed by partial 
lyophilization; and  the remaining  material was pumped directly onto 
a reverse-phase HPLC C, column (0.46 X 25 cm; Vydac, Hespevia, 
CA) previously equilibrated  with 0.04% trifluoroacetic acid in H,O. 
The column was washed with 0.04% trifluoroacetic acid until absorb- 
ance (214 nm) returned to base line and was then eluted using a 
linear  gradient of 0-35% acetonitrile for 30 min. This was  followed 
by isocratic elution for 20 min and  then a  linear  gradient to 100% 
acetonitrile over 30 min. Fractions containing IGF binding  activity 
eluted between 30 and 35% acetonitrile. The  IGFBPs were incom- 
pletely separated,  but did elute in the following sequence: IGFBP-5, 
-4, and -3, followed by IGFBP-8. Recovery of total  IGFBP activity 
was 85%. Fractions containing  predominantly  either IGFBP-4 or -5 
(100-200  pg of total protein/column) were pooled and diluted  with 
Hz0 to a final concentration of 0.04% trifluoroacetic acid, 10% 
acetonitrile and were then reapplied to a Vydac C4 column (0.46 X 
2.5 cm). The column was eluted with a linear gradient (0-20% 
acetonitrile) over 10  min, followed  by a 40-min linear  gradient of  20- 
40% acetonitrile. The  IGFBPs eluted between 23 and 28% acetoni- 
trile. The purity of the  IGFBP-5  and -4 fractions was determined by 
SDS-PAGE with silver staining. Fractions  that contained  a  mixture 
of intact  IGFBP-4  and -5 were pooled and rerun. The fractions that 
were eluted at  22-23% acetonitrile when analyzed by SDS-PAGE and 
silver staining were noted to  contain two  bands (Mr 23,000 and 18,OO). 
Ligand blotting  using  lZ5I-IGF-I showed no  detectable binding activ- 
ity; however, when lZ51-IGF-II was used, both fragments were de- 
tected. These fractions were further purified and submitted for N- 
terminal  amino acid sequence analysis. The concentrations of pure 
intact  IGFBP-4  and -5 were low, e.g. 1-5 pg/ml. Since attempts  to 
concentrate the samples by lyophilization resulted in a 50% loss of 
each  protein, the fractions containing each protein were pooled sep- 
arately, and  then each pool was reapplied to  the C4 column and eluted 
using a linear gradient of 0-100% acetonitrile over 40 min. Single 
fractions  containing an -20-25 pg/ml concentration of each  protein 
were obtained. Final purity was assessed by SDS-PAGE followed by 
silver staining, ligand blotting, or amino acid sequence analysis. 
N-terminal Sequence Determination-Pure preparations of intact 
IGFBP-4 or -5 or the M,  23,000 and 18,000 fragments were lyophi- 
lized. Approximately 148 pmol of IGFBP-5,  125 pmol of IGFBP-4, 
and 420 pmol of the fragments were reconstituted separately in 
HPLC-grade water (Burdick & Jackson Laboratories Inc., Muskegon, 
MI). Each was sequenced directly  using an Applied Biosystems Model 
470A Sequencer equipped with on-line analysis using an Applied 
Biosystems Model 120A phenylthiohydantoin  analyzer. To verify the 
presence of cysteine residues, 180 pmol of each of the  intact proteins 
were reduced and S-pyridylethylated in solution according to the 
method of Hawke and Yuan (13)  prior to sequencing. 
IGF Binding Activity in Chromatographic Fractions-IGF binding 
activity was determined using a polyethylene glycol precipitation 
method (14). In brief, conditioned media aliquots were incubated with 
20,000 cpm of lZ51-IGF-I for 1 h at  22 "C and  pH 6.0. Bound "'I-IGF- 
I was separated from unbound by precipitation with 0.25% human 
globulin and 12.5% polyethylene glycol. 
Generation of Antisera to IGFBP-4  and -5-Intact pure IGFBP-4 
was concentrated, and -80  pg were reconstituted in 800 pl of water 
and added to  an equal volume of Freund's complete adjuvant  (Sigma). 
The inoculum was thoroughly mixed to reach an emulsion, and 25 pl 
were injected intradermally at  multiple  sites in a single New Zealand 
White rabbit (Franklin Rabbitry,  Wake  Forest,  NC). After 4 weeks, 
the injection was repeated  using 30 pg of IGFBP-4 in 1 ml of 50% 
Freund's incomplete  adjuvant. Thereafter,  the rabbit was bled at  3- 
week intervals and was reimmunized with 20  pg  of protein five times. 
The  antisera used in  these studies were obtained at  the  fourth  and 
fifth bleeds. They were specific for IGFBP-4 as proven by their 
inability to react  with 50 ng of pure  IGFBP-1, -3, or -5 by immuno- 
blotting. In contrast, 0.5 ng of the pure IGFBP-4 could be detected 
by this method. Antisera  against IGFBP-5 were prepared in a  similar 
manner, with the exception that  intact  IGFBP-5 was not  immuno- 
genic in rabbits.  Therefore, two fragments of IGFBP-5 with molecular 
weight estimates of 23,000 and 18,000 were pooled, and  the pool was 
used as  an immunogen. These fragments were sequenced, and  it was 
shown that  the first  nine amino acid assignments were identical to 
the N terminus of intact IGFBP-5. A guinea pig was immunized with 
90 pg of the fragment mixture intradermally, followed by a repeat 
injection of 40 pg subcutaneously after 4 weeks. The animal was 
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reimmunized with 25  pg at  4-week intervals. The guinea pig was bled 
every 2 weeks. These studies used antiserum from the  third bleed. 
The antiserum had no  cross-reactivity  with 50 ng of IGFBP-1, -2, -3, 
or -4, but could detect 0.2 ng of intact IGFBP-5. 
Ligand Blotting-To study the regulation of distinct forms of 
IGFBP, ligand blot analyses were performed. Aliquots of conditioned 
media or of cellular extracts were electrophoresed through 12.5% 
SDS-polyacrylamide gel (15). The separated proteins were then  trans- 
ferred to nitrocellulose filters. The  transfer  and probing buffers were 
as described by Hossenlopp et al. (16). The membranes were probed 
for IGF binding activity by incubation with -500,000 cpm of "'I- 
IGF-I overnight at  4 "C. The filters were then washed as described 
(16). IGFBP bands were visualized by autoradiography and were 
quantified by scanning densitometry. To correctly quantify these 
changes, the  band  intensities of increasing concentrations of pure 
IGFBP-5  that had been ligand-blotted were analyzed. It was deter- 
mined that  the increases in  band  intensity were linear between 1000 
and 25,000 scanning units. Molecular weights were estimated by 
comparing the electrophoretic mobility of the  IGFBPs  to prestained 
molecular weight markers. 
Immunoblotting-Conditioned media samples were electropho- 
resed and transferred to nitrocellulose filters as described above for 
ligand blotting analysis. The polyclonal antiserum against human 
IGFBP-1  that was used had been prepared as described previously 
(17).  The polyclonal antiserum  against bovine IGFBP-2 was prepared 
as previously described (18) and was used at  a  final  dilution of  1:lOOO. 
IGFBP-3 antiserum was prepared as described for IGFBP-1 with the 
following modifications. Seventy micrograms of recombinant human 
IGFBP-3 (a gift from Biogrowth, Inc.) were used for the primary 
immunization, and 20 pg were used for reimmunization. The  anti- 
serum obtained could detect 4 . 0  ng of IGFBP-3 at  a 1:lOOO dilution; 
and when tested at  a  final  dilution of  1:100, it  had no  cross-reactivity 
with IGFBP-1, -4, or  -5  and <1%  with IGFBP-2  (data  not shown). 
For immunoblot  analysis, nitrocellulose filters were incubated  with 
the appropriate  primary  immune  serum in Tris-buffered  saline  con- 
taining 1% BSA, pH 7.0, for 90 min at  room temperature unless 
stated otherwise. The filters were then rinsed three  times with Tris- 
buffered saline and incubated for 2  h  with anti-rabbit IgG-alkaline 
phosphatase conjugate at  a final dilution of 1:500 in Tris-buffered 
saline plus BSA, followed by two rinses with Tris-buffered saline 
containing 0.01% Tween 20. Bands were visualized using the 
ProtoBlot system immunoblotting  reagents following the technique 
recommended by the manufacturer  (Promega  Biotec). The lower limit 
of sensitivity for this technique  is -0.2 ng of human  IGFBP-2, 1 ng 
of IGFBP-1, and 1 ng of IGFBP-3.  Neither IGFBP-1  nor -2 antiserum 
cross-react  with IGFBP-3  at  the dilution used in these  studies. The 
antisera against IGFBP-5  and -4 were used at final  dilutions of  1:200 
and 1:1000, respectively. 
RNA Isolation-RNA was isolated from cell cultures by the guan- 
idinium  thiocyanate  method  (19) and was quantified by spectropho- 
tometry.  Poly(A)+ RNA was prepared from 1.0 mg of total cellular 
RNA (T98G cells) using an oligo(dT)-cellulose column as per the 
manufacturer's  instructions (Pharmacia). Two cycles of purification 
were used. 
Preparation of DNA Probes for  IGFBP-4 and -5"PCR was used 
to  prepare specific probes for human  IGFBP-4  and -5. To prepare  a 
human  IGFBP-4 cDNA probe, two sets of primers were designed. A 
set of two 27-mers in  the  5'  to 3' orientation  (5'-GATACT- 
GAATTCGGCTGCGGCTG(C/T)TGC-3') and a set of eight  27-mers 
in  the 3' to  5' orientation (5'-GTAGAGGAATTCGTC(A/G) 
CAGTT  (G/T)GG(A/G)AT-3') were synthesized. The primers were 
designed to amplify a 462-base pair  segment of DNA that was located 
in  the center of the protein-coding region (20). Both  sets of primers 
contained EcoRI sites at  the 5'-end. Two micrograms of poly(A)+ 
RNA from T98G cells were reverse-transcribed in a 2 0 4  reaction 
containing 0.1 M Tris, 0.15 M KC1, 0.02 M dithiothreitol, 0.006 M 
MgCl,, pH 8.3,  2.5 pg of BSA, 80 units of RNase  inhibitor, 0.5  pg  of 
random hexamers, 0.5 mM deoxynucleotide triphosphates, and 200 
units of Moloney murine leukemia virus reverse transcriptase. After 
30 min at  37 "C, 200 units of the enzyme were added again, and 
incubation was repeated. The reaction  mixture was adjusted to con- 
tain 17 mM Tris, pH 8.3, 50 mM KCl, 2 mM dithiothreitol, 2 mM 
MgC12, 198 p M  deoxynucleotide triphosphates,  and 0.12 pg/ml BSA 
in 100 pl. To allow amplification by PCR, the  5'-  and 3"primer sets 
were added at  1 and 4 p ~ ,  respectively. The reaction mixture was 
covered with mineral oil and heated for 3-5 min at  95 "C. After the 
addition of 5 units of DNA polymerase from Thermus aquaticus (Taq 
polymerase), the cycling reaction was initiated. Two initial cycles 
with an annealing temperature of 45  "C were followed  by 40 cycles 
with an annealing temperature of 55 "C. Melting and extension 
temperatures were 95  and 72 "C in all cycles, respectively. Ten micro- 
liters of the reaction  mixture were electrophoresed  through  a 1.5% 
agarose gel (Sea  Kem) to show that  the 462-base pair  product was 
amplified. Sizes were compared to  the relative migration of the bands 
in the DNA ladder. The remaining material was extracted with 
phenol/chloroform/isoamyl alcohol (25:24:1) and was then extracted 
with chloroform/isoamyl alcohol (24:l)  and precipitated with 0.3 M 
sodium acetate, pH 5.0, 67% ethanol. The dried DNA pellet was 
resuspended, digested with EcoRI, and separated by electrophoresis 
on  a  1.5% low melting temperature agarose gel (Nusieve).  The DNA 
of interest was excised from the gel and  then extracted with phenol 
only followed by chloroform/isoamyl alcohol (24:l) and was precipi- 
tated  as described above. The DNA was ligated into  the EcoRI site 
of the  pBS vector that  had been EcoRI-digested and whose 5'-ends 
had been dephosphorylated  using calf intestinal alkaline  phosphatase. 
The ligation proceeded for 4  h at  22 "C using 1.5 units of T, DNA 
ligase for 200 ng of DNA (vector:insert molar ratio of 1:4) in a total 
reaction volume of 5 pl. The reaction  mixture was then diluted to 25 
p1 with H20  and was used to  transfect Escherichia coli JM109 cells 
(21). Colonies were grown on Luria broth agar plates containing 
ampicillin (100 pg/ml). Isopropyl-1-thio-@-D-galactopyranoside and 
5-bromo-4-chloro-3-indolyl @-D-galactoside were added upon  plating 
to perform a white and blue colony assay. White colonies were 
collected and grown in 5 ml of Luria broth containing ampicillin for 
6 h. Plasmid DNA was prepared from a 1.5-ml culture using the rapid 
boiling DNA preparation (22). Positive clones were identified by 
EcoRI digest of the DNA followed by electrophoresis on a 1.5% 
agarose gel (Sea  Kem). An alkaline DNA preparation (21) was per- 
formed for some of the positive clones to sequence double-stranded 
DNA using the dideoxy sequencing method  (23). The DNA sequence 
of the amplified 462-base pair  product was identical to  the sequence 
published for human  IGFBP-4 (20, 24). 
The cDNA fragment of IGFBP-5 was prepared in the same manner 
as  IGFBP-4 with a few modifications. The sequence used for the 5' 
to 3'  primer was the same as  that used for IGFBP-4, and  the sequence 
for the 3' to  5' primer was a set of four 18-mers (5"GTCCCCATC- 
CAC(G/A)TA (C/T)TC-3'). The primers were designed to cover a 
region containing 627 base  pairs  within the protein-coding region of 
IGFBP-5 (25). An EcoRI site was contained only in the 5'-end of one 
set of primers. PCR was performed using 37 "C as the annealing 
temperature in the initial two cycles. Otherwise, temperatures were 
as described for amplifying IGFBP-4 DNA. The cloning vector was 
prepared by an SmaI digest followed by an EcoRI digest and was gel- 
purified as described above on an agarose gel (Seaplaque). The 
vector:insert molar ratio used in the ligation reaction was 1:3. The 
ligation reaction was allowed to proceed for 2  h at room temperature 
and  then overnight at  16 "C. Positive clones were identified by EcoRI/ 
Hind111 restriction digest. 
The IGFBP-3 cDNA probe was a full-length cDNA (2585 base 
pairs)  that had been cloned into pUC119 and was prepared as previ- 
ously described (26). 
Northern Blot Analysis-RNA samples were denatured by heating 
to 55 "C for 1 h  with 1 M glyoxal and 50% dimethyl sulfoxide in 10 
mM sodium phosphate,  pH 6.8. Samples  (15 pg in 12 pl) were com- 
bined with  3 pl of dye solution (0.1% bromphenol blue, 0.1% xylene 
cyanol, and 50% sucrose) and were subjected to electrophoresis on a 
1% agarose gel with  recirculating buffer (10 mM sodium phosphate, 
pH 6.8). To confirm that similar amounts of RNA were loaded, the 
gels were stained with  ethidium bromide, and ribosomal RNAs (28 S 
and 18 S) were visualized by UV transillumination. RNA was trans- 
ferred onto nylon membrane  filters  (Biotrans,  ICN Biomedical, Inc., 
Irvine, CA) using 20 X SSC (1 X SSC = 15 mM sodium citrate, 0.15 
M NaCl, pH 7.01, and  the filters were baked under vacuum for 2  h at 
80 "C. For hybridization, gel-purified DNA fragments of cDNAs cor- 
responding to IGFBP-4, -3, or -5 were labeled with [32P]dCTP by the 
random priming method (27). Prehybridization and hybridization 
were performed in a  solution of 1 mM EDTA, 0.25 M NaHP04,  pH 
7.2, 7% SDS (28), and 0.2 mg/ml denatured salmon  sperm DNA at 
55 "C for 12 and 24 h, respectively. Filters were washed in 2 X SSC, 
0.1% SDS for 15 min at  22 "C followed  by 15 min at 50 "C and were 
then washed in 0.1 X SSC, 0.1% SDS for 1 h at 65 "C. Autoradiog- 
raphy was performed at  -80 "C. Molecular weight estimation of the 
hybridizing band was obtained by comparison with the relative mi- 
gration rate of a commercial RNA ladder  containing 9.5-,  7.5-,  4.4-, 
2.4-, 1.4-, and 0.24-kb RNA standards. Changes in band intensity 
were analyzed by scanning densitometry. To determine linearity, 
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hetween 5.0 and  20 pg of total  RNA  from  T98G  cells  were  processed 
by  Northern blotting, and the scanning densitometry units were 
determined.  The  results were  linear  between  8000  and 24,000 scan- 
ning  units. 
RESULTS 
Conditioned medium from the GMlO fibroblast cell line 
was analyzed by ligand  blotting. Under basal  conditions, this 
cell  type  secreted predominantly  an  IGFBP  that migrated as 
a doublet between M ,  43,000 and 39,000 (Fig. 1). A previous 
study had  reported that  these two bands  represented  different 
glycosylation forms of IGFBP-3 (7). Bands with molecular 
weight estimates of 31,000 and 24,000 were also detected in 
the conditioned medium. IGFBP-3  antiserum  detected only 
the M ,  39,000 and 43,000 bands  and did not  react with the M ,  
31,000 or 24,000 band (Fig. 1). Because we had previously 
shown  that  the  abundance of the M ,  31,000 band was mark- 
edly stimulated by IGF-I (6), we wished to determine its 
identity. To determine if the M ,  31,000 and 24,000 bands were 
related  to  other forms of IGFBPs  that  had been previously 
characterized, these ligand blots were immunoblotted with 
antisera  that  are specific for human  IGFBP-1 (17) and bovine 
IGFBP-2 (18). Neither antisera reacted with these bands. 
Therefore,  the M ,  31,000 and 24,000 bands do not  appear  to 
be proteolytic  degradation products or deglycosylated forms 
of IGFBP-3 or intact  IGFBP-1  or -2. 
To determine  the molecular identity of the M ,  31,000 and 
24,000 forms of IGFBP, conditioned medium from T98G cells, 
which had been shown to secrete two IGFBPs of identical 
electrophoretic mobility, was used to purify these proteins. 
Approximately 900 pg  of the M ,  31,000 protein  and 1.2 mg of 
the M ,  24,000 protein were recovered during purification to 
homogeneity. Proof of purity was obtained by amino acid 
sequence determination of each  peak. N-terminal  amino acid 
sequence determination of the M ,  24,000 protein revealed that 
the  first 32 amino acids  had the following sequence: DEAI- 
AHCPPCSEEKLARCRPBVGCEELVREPG. This sequence 
is identical to  that published for human  IGFBP-4 (24).  Like- 
wise, the M ,  31,000 protein revealed the following N-terminal 
sequence: LGSFVHCEPCDEKALSMCPPSPLGCELVKE, 
corresponding to  the  first 30 residues of human  IGFBP-5 (25). 
Purified  IGFBP-4  and  -5 were then analyzed by silver staining 
and immunoblotting. SDS-PAGE with silver staining re- 
vealed a single band for IGFBP-5 with a molecular weight 
estimate of 31,000 (Fig. 2).  Antiserum  that was prepared from 
IGFBP-5 fragments  reacted  intensely  with this  band (Fig. 2) 
and detected concentrations  as low as 0.2 ng  (data  not  shown). 
IGFBP-4 migrated as a single band at  M ,  24,000 and  antisera 
prepared using this  protein reacted  with the M ,  24,000 band. 
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FIG. 1. Ligand and immunoblots of GMlO cell conditioned 
media  using IGFBP-1, -2,  or -3 antiserum. Conditioned  medium 
(24  h)  from  IGF-I  (50  ng/ml)-treated  fibroblast  cultures  was  ligand- 
blotted (lane A )  or immunoblotted  with  IGFBP-1 (lane C), IGFBP- 
2 (lane E ) ,  or IGFRP-3 (lane C) antiserum as detailed  under  "Exper- 
imental  Procedures." Lanes B, D, and F represent  pure  human 
IGFRP-1  (25  ng), bovine  IGFRP-2  (10  ng),  and  recombinant  human 
deglycosylated IGFRP-3  (25  ng), respectively.  Shown are the  relative 
positions of the molecular weight standards. The  arrows ( top to 
hottom) indicate  IGFRP-3, -2, and -1. 
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FIG. 2. Silver staining and immunoblot analysis of IGFBP- 
4 and -5. Twenty  nanograms of IGFBP-5  and -4 that were purified 
from  the  T98G cell conditioned  media  were  analyzed by silver  staining 
(SS) (lanes I and 3, respectively). The  pure  proteins were also 
electrophoresed and transferred onto nitrocellulose and then incu- 
bated  overnight  with  antiserum  that  was  specific for either  IGFBP-5 
or -4 (lanes 2 and 4, respectively).  Shown are the relative  positions of 
the molecular  weight  standards. To  confirm  that  the  antisera were 
specific, 20 p1 of conditioned  medium  from  T98G cells were  electro- 
phoresed  and  analyzed by ligand  blotting (lane 5 )  or by immunoblot- 
ting ( I B )  with  IGFBP-5  antiserum (lane 6 )  and  IGFBP-4  antiserum 
(lane 7). The arrows show the positions of intact immunoreactive 
IGFBP-5  and -4. A non-IGF-binding  immunoreactive  band is noted 
in lane 6. This band has identical electrophoretic mobility to a 
fragment of IGFBP-5  that was  purified  from  T98G  cell  conditioned 
medium. 
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FIG. 3. Immunoblot of fibroblast conditioned medium with 
IGFBP-3, -4, or -5 antiserum. Confluent  cultures of GMlO cells 
were exposed to EMEM (-) or EMEM plus 100 ng/ml IGF-I (+). 
The conditioned media samples were analyzed by ligand blotting 
(lanes I and 2) or by immunoblotting (lanes 3-8). Lanes 3 and 4, 5 
and 6, and 7 and 8 were exposed to  IGFBP-4, -5, and -3 antisera, 
respectively. The conditioned  media  used for the  immunoblots were 
concentrated  10-fold.  Shown are the molecular weight standards.  The 
IGFBP-5 antiserum was prepared using IGFBP-5 fragments and 
appears  to have a higher affinity for fragments compared to intact 
protein.  Therefore,  the  use of this  antiserum  may  overestimate  frag- 
ment  abundance  relative  to  changes  in  intact  IGFBP-5. 
When conditioned medium obtained from the human glio- 
blastoma cells (a cell line that secretes IGFBP-2, -3, -4, and - 
5 )  was immunoblotted  with IGFBP-5  antiserum, only the M,  
31,000 band was reactive (Fig. 2). Similarly, the IGFBP-4 
antiserum did not cross-react  with IGFBP-3, -5, and -2, but 
did recognize the M ,  24,000 band (Fig. 3). To further  test  the 
specificity of these  antisera, conditioned medium from 
AG2804 cells was analyzed by immunoblotting. This cell line 
has been  shown to secrete an M ,  32,000 form of IGFBP (11) 
with an  N-terminal sequence  identical to  IGFBP-6 (11, 25). 
Neither IGFBP-4 nor -5 antiserum bound to this protein 
(data  not  shown).  These  data indicate that  IGFBP-4  and -5 
were pure  and  that  the antibodies  are specific for the appro- 
priate forms of IGFBPs. 
To determine whether the M,  31,000 and 24,000 proteins 
in fibroblast conditioned medium corresponded to the pro- 
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teins purified  from T98G cell conditioned  medium, GMlO cell 
conditioned medium was analyzed. Ligand blotting showed 
the M ,  31,000 and 24,000 bands  and  that  the  intensity of the 
M, 31,000 band was stimulated 6-fold by IGF-I  exposure (Fig. 
3).  Immunoblotting  this ligand  blot with  IGFBP-5  antiserum 
showed that  the M ,  31,000 band could be detected  and  that 
the  intensity of the  immunoreactive  band was  increased fol- 
lowing IGF-I exposure. An intensely  staining M, 23,000 band 
was also detected.  This  band did not  bind  IGF-I,  as  shown  on 
the ligand blot. These findings suggest that  the polyclonal 
IGFBP-5  antiserum recognizes a protein  that  is  identical or 
nearly  identical  to  the purified IGFBP-5  and  that  its regula- 
tion by IGF-I is similar to the M, 31,000 band previously 
described (6, 7). The M, 24,000 IGFBP  secreted by the  GMlO 
fibroblasts  diminished  in  intensity following IGF-I exposure. 
Immunoblotting showed that  the M, 24,000 band was detected 
by IGFBP-4  antiserum  and  that  its  intensity decreased fol- 
lowing IGF-I exposure. This suggests that the M, 24,000 
protein  secreted by GMlO fibroblasts is very similar  or  iden- 
tical  to  IGFBP-4  and  that  its levels in  conditioned medium 
are  diminished by IGF-I  treatment.  The ligand blot  bands a t  
M ,  39,000 and 43,000 were recognized by antiserum  against 
IGFBP-3,  and  both ligand and  immunoblot  activities  in  GMlO 
conditioned  medium were increased by IGF-I  treatment. 
To  further  strengthen  the conclusion that  IGFBP-4  and  -5 
are synthesized by fibroblasts, specific cDNA probes were 
prepared using the polymerase chain reaction. cDNA se- 
quence  analysis revealed that  the  probes  contained  the  correct 
sequences  predicted  for IGFBP-4  and -5. As shown in Fig. 4, 
a single 6.0-kb messenger RNA band corresponding to the 
previously reported size of the human IGFBP-5 transcript 
(20) was detected  in RNA isolated from fibroblast  cultures. 
IGFBP-5 message was slightly increased (-40 and  29%,  re- 
spectively) following 6 and 12  h of exposure to  IGF-I (Fig. 4). 
No greater increase in band intensity could be detected in 
four  separate  experiments.  There was no  detectable  change 
in mRNA abundance in cultures that had been exposed to 
IGF-I for 24 h compared  to  controls.  Two  transcripts of 2.2 
and 2.0 kb were detected  with  the  IGFBP-4 cDNA  probe (Fig. 
5). Although scanning  densitometry showed minimal  changes 
in band intensity induced by IGF-I a t  12 and 24 h when 
corrected for the  amount of RNA  loaded per  lane, exposure 
to  IGF-I did not  result in  a change  in  mRNA  abundance  at 
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FIG. 4. IGFBP-5 mRNA  abundance  in   cul tured  human  f i -  
broblasts. Total cellular RNA was prepared as described under 
"Experimental Procedures" from GMlO cultures,  and 15-pg aliquots 
were  electrophoresed and  transferred  to a  nylon membrane  and  then 
hybridized  with a '"P-labeled human  IGFRP-5 cDNA probe (upper) .  
The arrow denotes  the  6-kb message that  is  present  in  these  cultures. 
The RNA samples loaded in lanes I ,  3, and 5 are from unstimulated 
human fetal fibroblast cultures, whereas the samples in lanes 2, 4,  
and 6 are from cultures that were exposed to IGF-I (50 ng/ml) for 
the times indicated. Lane 7 is  15 pg of total RNA  isolated  from the 
T98G cells. Also shown is the ethidium bromide staining of total 
RNA loaded in each lane (lower). Ribosomal RNA electrophoretic 
migration positions  are  denoted. 
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FIG. 5. IGFBP-4 mRNA abundance in cultured human fi-  
broblasts.  Human fihrohlast  RNA  was prepared as described for Fig. 
4, electrophoresed, and  transferred  to nylon  filters. The filters were 
probed  with a "'P-labeled human  IGFRP-4 cDNA probe. Two tran- 
scripts with  molecular  size estimates of 2.2 and 2.0 kb were detected. 
If higher stringency washes were used, the lower hand could he 
removed; however, there was a marked parallel  reduction in the 
intensity of the  upper  band. RNA samples loaded in lanes I ,  3. and 5 
are from unstimulated  cultures, whereas samples in lanes 2, 4, and 6 
are from cultures  t,hat were exposed to  IGF-I (50 ng/ml) for the  times 
indicated prior  to  harvesting  the  RNA. 




FIG. 6. Change  in  IGFBP-3 mRNA abundance following 
IGF-I exposure.  Total RNA (15 pg) from  quiescent GMlO fibroblast 
cultures  that  had been  exposed to  EMEM  alone (lane I ) ,  IGF-I (50 
ng/ml) (lane 2 ) ,  IGF-II(50  ng/ml) (lane 3), or forskolin (10 pM) (lane 
4 )  for 24 h was electrophoresed and  transferred  to nylon membranes. 
The RNA was  hybridized  with the:'2PP-labeled  human  IGFBP-3 cDNA 
probe.  A  single 2.4-kb transcript was detected  after autoradiography. 
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FIG. 7. Effect  of  forskolin  on IGFBP-4 and  -5 mRNA 
expression.  Confluent fibroblast  monolayers were incubated for 12 
h in EMEM alone (C) or in EMEM plus forskolin (10 p ~ )  ( F ) .  
Fifteen  micrograms of total  RNA were electrophoresed, transferred 
to nylon membranes,  and hybridized  with '"P-labeled IGFRP-5  and 
-4  cDNA  probes. The arrows indicate  the 6.0-kb transcript of IGFRP- 
5 and  the 2.2- and 2.0-kb transcripts of IGFBP-4. 
any time point. These findings show that IGF-I-induced 
changes  in  the levels of IGFBP-5  and -4 are  not primarily due 
to  changes in either  mRNA  transcription or altered mRNA 
degradation rates. In contrast, when changes in IGFBP-3 
mRNA were analyzed, a 2-fold increase (as determined by 
scanning densitometry) in the 2.4-kb transcript was noted 
following IGF-I exposure (Fig. 6). This corresponds to the 
relative change in protein abundance that occurs following 
IGF-I exposure. 
To determine whether other factors known to stimulate 
IGFBP  secretion were also  mediating their effects at  a  post- 
transcriptional level, fibroblast cultures were exposed to for- 
skolin (10 PM),  and  total RNA as well as conditioned medium 
were collected after 24 h. Northern blotting revealed that 
forskolin  increased IGFBP-4  and  -5 mRNA  abundance (Fig. 
7). Scanning densitometry showed that  the 2.2- and 2.0-kb 
forms of IGFBP-4  mRNA were increased 2.6- and 2.8-fold, 
respectively, and  that  IGFBP-5 was  increased 2.5-fold. This 
suggests that IGFBP-4 and -5 synthesis is regulated by 
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changes in intracellular CAMP at  the level of changes in 
mRNA abundance. In  contrast,  the  mechanism(s) by which 
IGF-I regulates IGFBP-4  and  -5 levels may  be post-transcrip- 
tional. 
Immunoblot analysis of GMlO conditioned medium with 
an IGFBP-5 antiserum revealed a prominant band a t  M ,  
23,000. This  band  had a  molecular  weight estimate  that was 
identical  to  one of the proteolytic fragments of IGFBP-5  that 
was purified  from T98G cell conditioned medium. N-terminal 
sequence analysis of the  T98G cell-derived fragment showed 
that  its 9 N-terminal residues were identical  to  the  N-terminal 
sequence of IGFBP-5,  proving  that  it was  a non-IGF-I-bind- 
ing fragment of that protein. To determine if the IGF-I- 
stimulated  increase  in  IGFBP-5 ligand blot  activity  in con- 
ditioned medium  was  associated with a  decrease in  the  amount 
of M ,  23,000 fragment  generated, GMlO  cells were incubated 
with  pure  IGFBP-5 (1.0 pg/ml)  in the presence or  absence of 
IGF-I  or -11 or  insulin for 4 h. Exposure  to  either  IGF-I  or -11 
(200 ng/ml),  but  not  insulin  (5  pg/ml),  inhibited  the  formation 
of the M ,  23,000 fragment (Fig. 8). To determine  the specific- 
ity of this  protease,  pure  IGFBP-1 was added  to  the  cultures, 
and its abundance was analyzed after 24 h. No proteolytic 
degradation  fragments were noted  after  immunoblotting  with 
IGFBP-1  antisera. 
To  determine  the specificity of the  fibroblast response to 
IGF-I,  confluent  cultures were incubated  with  concentrations 
of insulin  and IGF-I1 that were sufficient  to  stimulate  IGF-I 
receptor activation. In contrast to IGF-I and -11, insulin 
stimulated  secretion of IGFBP-4  but  had  no effect on  IGFBP- 
3 and -5 (Fig. 9). As noted previously, IGFBP-3  and  -5 were 
preferentially induced  by both  IGF-I  and -11. These  increases 
were dependent  upon  the  concentrations of IGF-I  and -11 that 
were used. Scanning densitometry showed that IGF-I (100 
ng/ml) invoked  a 6.5-fold increase  in  IGFBP-5, whereas the 
IGFBP-3 band intensity increased only 2.1-fold (Table I). 
Similarly, IGF-I1  induced  only  a 1.4-fold increase in IGFBP- 
3 band  intensity,  but increased IGFBP-5 by %fold. Secretion 
of IGFBP-4 was inhibited by IGF-I  and -11 and  stimulated 
3.2-fold by insulin. 
The regulation of secretion of IGFBPs by other  hormones 
and growth factors was also  analyzed. Scanning  densitometry 
showed that forskolin  increased conditioned medium levels of 
IGFBP-3  and  -5 1.3- and 3.5-fold, respectively  (Fig. 1OA). In 
contrast,  TGF-P  and  dexamethasone  appeared  to ecrease the 
levels of both of these  forms of IGFBP. Cycloheximide  com- 
pletely  inhibited  the  secretion of all  forms of IGFBP.  Platelet- 
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FIG. 8. Effect of IGF-I and -11 and insulin on IGFBP-5 
fragment  formation. Pure IGFBP-5 was incubated  with  quiescent 
fibroblast cultures in EMEM for 4 h a t  37 "C. At that time, the 
conditioned media samples were removed, and 25 p1 of each  sample 
were  analyzed by SDS-PAGE and  immunoblotting. Lane I contains 
25 ng of pure IGFBP-5 and shows no fragment. Lane 2 shows an 
identical  amount of IGFBP-5 that  had been  exposed to  cultures  that 
contained  no additives during  the 4-h incubation a t  37 "C. It  shows 
the appearance of an M, 23,000 fragment. Lanes 3 and 4 contain 
conditioned medium  from cultures that had been incubated with 1.0 
pg/ml IGFBP-5 and 200 ng/ml IGF-I or -11, respectively. Lane 5 
shows conditioned  medium  from  a culture that was  exposed to 
IGFBP-5 plus 5 pg/ml human  insulin. 
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FIG. 9. Regulation of IGFBP abundance by IGF-I and -11 
and insulin. Confluent  cultures of human  fetal fibroblasts (GMIO 
cells) were incubated with or without IGF-I and insulin ( A )  or IGF- 
I1 ( R )  for 24 h. Conditioned media samples were analyzed by ligand 
blotting as described for Fig. 1. The molecular weights of protein 
standards  run  in parallel lanes  are indicated. 
TABLE I 
Effect of IGF-I and -II  and  insulin on IGFRP abundance 
in  GMlO cell conditioned  media 
IGFBP 

























































" Areas represent  densitometry  units from Fig. 9. The M, 39,000- 
43,000 IGFBP appears  as a  doublet, and  due  to difficulty in distin- 
guishing  between the  peaks by scanning  densitometry analysis, the 
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FIG. 10. Regulation of abundance of IGFBPs in GMlO cells 
and their levels  in conditioned medium. Confluent monolayers 
were treated with TGF-p (1 ng/ml) (lane 2), dexamethasone (lo-" M) 
(lane 3 ) ,  IGF-I  (50 ng/ml) (lane 4 ) ,  cycloheximide (25 pg/ml) (lane 
5), or forskolin (10 /IM) (lane 6 )  and were compared to control  cultures 
(lane I). After 24 h, conditioned medium was  collected, and  the cells 
were solubilized with  Triton X-100. A ,  IGFBPs in fibroblast  condi- 
tioned medium; R, IGFBPs found in Triton X-100-solubilized cells. 
Shown  are  the relative positions of molecular weight standards. 
derived  growth factor, fibroblast  growth  factor,  estradiol, and 
progesterone  had  no effect (data  not shown). 
IGFBPs  on  fibroblast  surfaces have been shown to modu- 
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late IGF-I binding to IGF-I receptors (29). Therefore, the 
amount of the various forms of cell-associated IGFBPs was 
determined under basal conditions and after exposure to 
modulators of IGFBP secretion. Fig. 1OB shows the abun- 
dance of the various forms of IGFBPs  that were associated 
with cellular extracts. The cell-associated IGFBPs showed 
relative changes in their abundance that paralleled the 
changes  found  in the culture media. IGF-I induced significant 
increases  in cell-associated IGFBP-3 and -5. 
DISCUSSION 
This study  demonstrates that cultured  human fibroblasts 
secrete three structurally distinct forms of IGFBPs. Four 
bands are  detected by SDS-PAGE however, the two bands 
with molecular weight estimates of  39,000 and 43,000 appear 
to represent  different glycosylation variants of IGFBP-3 since 
they are  both immunoprecipitable with IGFBP-3 antiserum 
(7) and both react with IGFBP-3 antiserum by immunoblot- 
ting. Scanning densitometry showed that these two forms 
constituted -7040% of the IGF-I binding activity in the 
basal state. Several other published studies have also shown 
that these two forms are  the predominant species of IGFBP 
secreted by this cell type (6, 7 ) .  
Whereas IGFBP-3 is the predominant form released by 
human fibroblast cultures,  these cells also release detectable 
quantities of M ,  31,000 and 24,000 forms. The molecular 
identities of these forms were determined to be  IGFBP-5 and 
-4, respectively. This was proven by purifying these proteins 
to homogeneity from a glioblastoma cell line, establishing 
their identities with amino acid sequencing, and preparing 
specific antisera. The IGFBP-4 antiserum bound the M ,  
24,000 form and  the IGFBP-5  antiserum bound the M, 31,000 
form of IGFBP  that were present  in the fibroblast conditioned 
medium and did not recognize other forms of IGFBPs detected 
by ligand blotting. Further proof  was provided by the obser- 
vation that  the cDNA probes for these two transcripts hy- 
bridized specifically to mRNAs that had molecular weight 
estimates that were identical to those  reported for IGFBP-4 
and -5 (20, 24). Martin et al. (11) have reported that  trans- 
formed human fibroblast cultures secrete a form of IGFBP 
that  has  an electrophoretic mobility similar to  that of IGFBP- 
5. However, that protein  has  a  different  N-terminal sequence, 
and our IGFBP-5 antiserum did not recognize that protein in 
transformed fibroblast conditioned medium. Based on  these 
findings, we conclude that the M ,  31,000 IGFBP in the 
conditioned medium is IGFBP-5  and  that  the M, 24,000 form 
is IGFBP-4. 
Although IGFBP-5 was a minor component of the total 
IGFBP activity in fibroblast conditioned medium obtained 
from unstimulated cultures, its abundance in conditioned 
medium was enhanced 6-8-fold  following exposure to IGF-I 
or -11. This confirms our previous finding (6) and that of 
Martin  and Baxter ( 7 )  that showed an 8.4-fold induction of 
an  M,  31,000 protein in conditioned medium from a  neonatal 
fibroblast cell line. Clearly, this 6-%fold induction in  IGFBP- 
5 by IGF-I and -11 has the potential to be a major modulator 
of the cellular response to  the IGFs. We have noted that  an 
M ,  31,000 IGFBP is associated with fibroblast surfaces and is 
released from fibroblast surfaces with IGFBP-3 during  bind- 
ing assays (4) and that the released IGFBP-5 alters IGF 
association with cell-surface binding sites. In addition, An- 
dress and Birbaum (30)  reported that  IGFBP-5 released by a 
human osteoblast cell line can potentiate  the mitogenic effect 
of IGF-I by %fold on this same cell type. Therfore, like 
IGFBP-3, IGFBP-5 has the potential to be an important 
modulator of IGF-I binding to fibroblast surfaces and could 
modify the fibroblast growth response to IGF-I. Its regulation 
by exposure to IGF-I suggests a model in which these growth 
factors may  be able to autoregulate their interaction with cell- 
surface binding sites. 
The change that occurred in IGFBP-5 binding activity in 
response to IGF-I and -11 did not appear to be totally ex- 
plained by changes in mRNA abundance. In 6-h stimulated 
cultures, IGF-I induced a 43% increase in IGFBP-5 mRNA 
abundance; but  after 24 h,  no change was detectable. There- 
fore, this small change in IGFBP-5 mRNA expression appears 
to be an early effect that is not  quantitatively similar to  the 
6-&fold increase in binding protein  abundance that was de- 
tected in the conditioned medium. In contrast, IGFBP-3 
mRNA was increased -2-fold in response to IGF-I, which  is 
similar to  the change  in binding protein  abundance in media. 
Likewise, when quiescent cultures were  exposed to  forskolin, 
a 2.5-fold increase in IGFBP-5 mRNA abundance and a 3.5- 
fold increase in  protein levels  were noted, suggesting that  the 
forskolin-mediated change in binding protein abundance was 
mediated by increased protein  synthesis and was distinct from 
the mechanism by which the effects of IGF-I and -11 were 
mediated. 
Since insulin  can  bind to  the IGF-I receptor, it would have 
been predicted that insulin exposure would result in an  in- 
crease in the abundance of IGFBP-5 in conditioned medium. 
However, insulin had no effect, suggesting that  the difference 
may be related to the fact that insulin cannot bind to  the 
IGFBPs. We have previously reported that  IGF analogs that 
have reduced binding affinity for IGFBPs did not alter the 
level of the M ,  31,000 IGFBP  that was detected (31). More 
important,  an analog that did not bind to  the IGF-I receptor, 
but did bind the binding proteins, was equipotent  in  stimu- 
lating an increase in the M, 31,000 form of IGFBP. These 
results suggest that IGF-I and -11 must associate with IGFBP- 
5 to stimulate the increase in detectable IGFBP-5  in condi- 
tioned medium and  that receptor binding is not required. It 
would be difficult to invoke a mechanism to explain this 
change that was based solely on increased mRNA abundance. 
Therefore, it seemed reasonable that  this response might be 
related to  the disappearance of IGFBP-5 fragments that were 
detected by immunoblotting in conditioned medium from 
IGF-treated  cultures. The addition of IGF-I or -11 to cultures 
containing intact pure IGFBP-5 resulted in diminution of 
fragment  band  intensity, suggesting that when the IGFs bind 
to IGFBP-5  in the media, proteolytic cleavage of this protein 
is inhibited. Although we have not definitively demonstrated 
the presence of a protease that degrades IGFBP-5, our results 
suggest that IGF-I is indirectly increasing IGFBP-5 abun- 
dance by inhibiting its proteolysis. Since insulin does not bind 
to IGFBP-5 and does not inhibit the formation of its M ,  
23,000 fragment, this supports the conclusion that IGF-I and 
-11 are inhibiting formation of the M,  23,000 fragment by 
binding to  the  intact binding protein. We propose that  this 
change accounts for part of the 6-%fold increase in IGFBP- 
5 that is induced by IGF-I and -11. However, since the increase 
in  intact  IGFBP-5 was not always accompanied by a concom- 
itant decrease in fragments (Fig. 3), we cannot exclude the 
possibility that IGF-I and -11 may have a direct effect on 
IGFBP-5 secretion. The importance of IGF-induced inhibi- 
tion of IGFBP-5 proteolysis is  that  it could provide a  distinct 
means for modulating the effect of the IGFs on this cell type 
and for regulating the  amount of IGFs that are available to 
bind  to receptors, extracellular  matrix, or  other cell surface- 
associated binding sites. Because IGFBP-5  has been shown 
to  potentiate  the ffects of IGF-I  on  cultured osteoblasts (30), 
it appears that  this may  be a positive feedback system wherein 
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the effect of IGF-I is augmented by modulating IGFBP pro- 
teolytic activity. This interesting potential mechanism de- 
serves further study. 
This response appears to be specific for IGFBP-5 since no 
fragments of IGFBP-3 or -4 were detected. Furthermore, the 
band intensity of IGFBP-4 decreased after exposure to IGF- 
I,  and  this change did not appear to be due to acceleration of 
proteolysis. However, no change in IGFBP-4 mRNA abun- 
dance was noted, suggesting that  the effect was mediated by 
inhibiting its release into medium. Because IGFBP-4 has been 
shown to be a potent inhibitor of IGF-mediated cell growth 
(32), coordinate stimulation of IGFBP-5 with concomitant 
inhibition of IGFBP-4 by IGF-I would provide a mechanism 
for regulating the effects of these binding proteins to allow 
for induction of a mitogenic signal by IGF-I. Likewise, agents 
such as forskolin that increase IGFBP-4 might inhibit IGF- 
mediated fibroblast growth through this mechanism. Whether 
or not such coordinate signaling occurs in other cell types 
deserves further analysis. 
Control of IGFBP-3 secretion by cultured  fibroblasts has 
been analyzed by several investigators. Martin and Baxter 
(33) have reported that TGF-/3 induces a 4-fold increase in 
IGFBP-3 secretion. We detected no effect of TGF-P, but our 
cultures were  grown in calf serum, whereas theirs were  grown 
in fetal bovine serum. Because culturing fibroblasts in fetal 
bovine serum results  in  a decrease in the basal rate of IGFBP- 
3 secretion,’ the difference in our results could be due to  the 
presence of  lower amounts of TGF-8 in calf serum or some 
other factor that is necessary for TGF-/3 to stimulate IGFBP- 
3 secretion. Our study also shows that forskolin caused an 
increase in IGFBP-3. In addition, in  this study and in that 
reported by Martin  and Baxter (7), IGF-I and -11 increase the 
secretion of IGFBP-3, and  this change appears to be due to 
enhanced synthesis. We have shown that IGFBP-3 that is 
released into culture medium by fibroblasts can directly alter 
IGF-I interaction with cell-surface binding sites (34) since its 
affinity for IGF-I is significantly greater than  that of the IGF- 
I receptor. Both Blum et al. (35) and DeMellow and Baxter 
(8) have shown that exposure of fibroblast cultures to  IGFBP- 
3 potentiates the cellular growth response to IGF-I.  Therefore, 
factors that control the secretion of IGFBP-3 in fibroblasts, 
such as IGF-I or CAMP, may modulate IGF interaction  with 
the cell-surface binding sites and cellular growth responses. 
Likewise, because unsaturated  IGFBP-3 in medium can in- 
hibit IGF binding (34) and cell growth (8), coordinate regu- 
lation of IGFBP-3 secretion may  be a mechanism for deter- 
mining whether IGFBP-3  potentiates or inhibits IGF  target 
cell actions. 
These results provide several potential mechanisms by 
which the IGFs may regulate IGFBP abundance in fibroblast 
conditioned medium. Because the  IGFBPs are modulators of 
cellular responsiveness to  the IGFs, delineation of these mech- 
anisms may provide new insights into how this family of 
growth factors  functions to stimulate cell growth. 
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